Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Disability
Colonic epithelial primary cells
MARKER
Clinical trial
Anti-TNF agents
Safety
Ustekinumab
Venous thromboembolism
Contraindication
Microbiote
Patient-reported outcome
18 FDG-PET/CT
Fecal microbiota
Cell adhesion
Maintenance therapy
Inhibitor
IL23
Inclusion
Tailored therapy
Heart disease risk factors
Colorectal cancer Colibactin and lipids
Upper gastrointestinal tract
Gene methylation
MALT
Rituximab
RISK
Acceptability
Bactéries
Effectiveness
Crohn’s disease
Clinical guidelines
Colectomy
DNA METHYLATION
Intestinal crypts
Genes
Crohn's disease
Epigénétiques
IBD
Epigenetics
Disease progression
Rituximab plus chlorambucil
Therapeutics
Bacteria
Helicobacter pylori
Dysbiosis
Methylation
Consensus
Tuberculosis
COLON-CANCER
Kidney diseases
Biomarker
DNA methylation
IL12
Drug
Dysbiose
Méthylation
Parvimonas micra
MICROBIOTA
Patients experience
Colon cancer
Original Article Clinical
Cost effectiveness
Gènes
Ulcerative colitis
Eligibility
Survival
Vedolizumab
Over 80s
Immunosuppressant
HIV
Immune cells
Alkylating agents
Cancer
Gene expression
Primary sclerosing cholangitis
T1118 translocation
Microbiota
Algorithm
Disease Progression
Neoadjuvant chemotherapy
CARCINOGENESIS
Eradication
Monitoring
Thérapie ciblée
Small molecules
PCR
Inflammatory Bowel Diseases
Colorectal cancer
MORTALITY
Biologics
Endoscopic treatment
Colon
Resistance
Anti-TNF
Inflammatory bowel diseases
Résistance
Screening
Stricture
Inflammatory bowel disease
Surgery
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|